March 5 (Reuters) - Shares of Swiss skincare company Galderma opened higher on Thursday after it reported 17.7% growth in full-year net sales and gave an upbeat guidance for 2026. The annual net
Galderma Lifts 2026 Guidance After Strong Sales, Shares Jump 7 Percent
Galderma Reports Robust Financial Performance and Upbeat Outlook
Strong Full-Year Net Sales Growth
March 5 (Reuters) - Shares of Swiss skincare company Galderma opened higher on Thursday after it reported 17.7% growth in full-year net sales and gave an upbeat guidance for 2026.
Therapeutic Dermatology Drives Revenue
The annual net sales were $5.21 billion, with the strongest growth coming from its Therapeutic Dermatology business, where sales grew more than 50% largely thanks to the recently launched Nemluvio product, which is used to treat chronic skin conditions atopic dermatitis and prurigo nodularis.
2026 Guidance and Market Reaction
Sales and Profit Margin Forecast
The company expects net sales growth of 17% to 20% and a core profit margin of about 26% on a constant-currency basis for 2026.
Share Price Surge
Analyst Commentary
The shares gained around 7% by 0850 GMT, with Vontobel analysts saying the guidance was stronger than expected.
(Reporting by Marleen Kaesebier in Gdansk, editing by Milla Nissi-Prussak)
